Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Director of CDC resigns over financial conflicts: officials

Dr. Brenda Fitzgerald resigned her post as director of the U.S. Centers for Disease Control and Prevention over financial conflicts of interest, the U.S. Department of Health and Human Services (HHS) said.

Read More »

Boston’s Juniper Pharma Suspends Program, Cuts 8% of R&D Jobs and CMO Steps Down

Juniper Pharmaceuticals, after a strategic evaluation, decided to prioritize its resources on the company’s core businesses of Crinone progesterone gel and Juniper Pharma Services. As a result of the changes, Juniper plans to lay off 8 percent of its staff, mostly in the new product research-and-development areas.

Read More »

As Its CEO Retires, Cerecor Divests Depression Drug to Pharma Giant in $45 Million Deal

One day after the abrupt resignation of Chief Executive Officer Uli Hacksell, Cerecor Inc. announced that the company was divesting a drug therapy for major depressive order to Janssen Pharmaceuticals for up to $45 million.

Read More »

Novogen Restructures, Board to Take Pay Cuts

Novogen updated investors on the company’s strategic review of operations. On June 8, 2017, Iain Ross was appointed as chairman, which triggered the review by the board and management team.

Read More »

Gemphire Shares Drop on Disappointing Phase II Results for LDL Drug

Shares of Gemphire Therapeutics plunged more than 51 percent in morning trading after the company’s Phase IIb anti-cholesterol drug gemcabene failed to meet analyst expectations.

Read More »

OvaScience Slashes Workforce, Replaces CEO

OvaScience named a new chief executive officer and slashed its employee count by half.

Read More »

Akari CEO Abruptly Steps Down Amid Investigation Into Phase II Trial Data

A little more than two weeks after being placed on administrative leave, Gur Roshwalb – chief executive officer of Akari Therapeutics – resigned his position.

Read More »

Novelion CEO quits Novo Nordisk board due to NASH conflict

Danish drugmaker Novo Nordisk said the chief executive of Canadian biotech company Novelion Therapeutics had left its board with immediate effect due to “a potential conflict of interest.”

Read More »

Immunomedics CEO, COO Exit

Immunomedics’ chief executive office and chief scientific officer will step down. Also, Seattle Genetics backed out of a $2 billion deal with the company.

Read More »

Regulus CEO Out, 30 Percent of Workforce Slashed in Restructuring

Shares of Regulus Therapeutics were down more than 31 percent in premarket trading as its chief executive officer resigns amid an ongoing clinical hold of its lead product and the company initiates a corporate restructuring plan that includes the termination of 30 percent of employees.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom